Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Surgery for malignant pleural mesothelioma].

R Giudicelli1

  • 1Service de Chirurgie Thoracique, Hôpital Sainte-Marguerite, 270, boulevard Sainte-Marguerite, BP 29, 13274 Marseille Cedex 9. RGIUDICELLI@mail.ap-hm.fr

Revue De Pneumologie Clinique
|May 11, 2004
PubMed
Summary

Malignant pleural mesothelioma (MPM) treatment combines surgery, radiation, and chemotherapy. Advanced staging and epithelial histology improve outcomes with multimodal therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Action of yohimbine on the cardiovascular effects of diphenolic amino alcohols apparent to adrenaline.

Comptes rendus des seances de la Societe de biologie et de ses filiales·2010
Same author

[Acute mediastinitis except in a context of cardiac surgery].

Revue de pneumologie clinique·2010
Same author

Dehiscences of the bronchial joining after pneumonectomy for cancers: Incidence, gravity and risk factor.

Le Mali medical·2009
Same author

[Respiratory complications after oesophagectomy for cancer].

Revue des maladies respiratoires·2008
Same author

[Malignant pleural mesothelioma: role of excisional surgery].

Revue des maladies respiratoires·2007
Same author

[Malignant mesothelioma of the pleura: place of surgery].

Revue des maladies respiratoires·2006

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Medical Oncology

Context:

  • Malignant pleural mesothelioma (MPM) is an aggressive cancer linked to asbestos exposure.
  • MPM incidence has been rising, with a projected peak around 2010-2020.
  • Current treatment paradigms are guided by the Mesothelioma Interest Group TNM staging system.

Purpose:

  • To outline current therapeutic strategies for malignant pleural mesothelioma.
  • To detail treatment approaches based on disease stage and patient factors.
  • To highlight recent advancements and their impact on treatment outcomes.

Summary:

  • Early-stage MPM (Stage Ia) typically involves neoadjuvant intrapleural therapy with cytokines followed by pleurectomy.
  • Advanced stages (Ib, II, III) utilize a multimodal approach including extrapleural pneumonectomy, radiotherapy, and cisplatin-based chemotherapy.
  • Stage IV (unresectable) disease is managed with palliative treatment, with newer drugs showing promise.

Impact:

  • Multimodal therapy shows favorable results, particularly for patients with epithelial histology, negative resection margins, and no lymph node metastasis.
  • Encouraging early results suggest that novel drugs may lead to more optimal MPM treatment.
  • The TNM staging system provides a framework for consistent and effective treatment planning.

Related Experiment Videos